← All trials
NCT02599480
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2016
- Primary completion
- Dec 1, 2019
- Completion date
- Jan 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 297
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Université catholique de LouvainLead sponsor
- University of AthensCollaborator
- Wroclaw Medical UniversityCollaborator
- University of GoettingenCollaborator
- European Clinical Research Infrastructure NetworkCollaborator
- European Society of CardiologyCollaborator
- European CommissionCollaborator
- University of BresciaCollaborator
- University of LisbonCollaborator
- Université catholique de LouvainSponsor investigator
- University of NantesCollaborator
- University of OxfordCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.